Esophageal voice tends to be difficult to learn and patients are often only able to talk in short phrases with a quiet voice. lisp - a speech impairment that is also known as sigmatism. speech sound disorder - Speech-sound disorders (SSD) involve impairments in speech-sound production and range from mild articulation issues involving a limited number of speech sounds to more severe phonologic disorders involving multiple errors in speech-sound production and reduced intelligibility. stuttering - a speech disorder in which sounds, syllables, or words are repeated or last longer than normal. These problems cause a break in the flow of speech (called disfluency). See also
References
Further reading
Cherney LR, Gardner P, Logemann JA,  et al. (2010). "The role of speech-language pathology and audiology in the optimal management of the service member returning from Iraq or Afghanistan with a blast-related head injury: position of the Communication Sciences and Disorders Clinical Trials Research Group". J Head Trauma Rehabil. 25 (3): 219–24. doi:10.1097/HTR.0b013e3181dc82c1. PMID 20473095. S2CID 8929365. Wong PC, Perrachione TK, Gunasekera G, Chandrasekaran B (August 2009). "Communication disorders in speakers of tone languages: etiological bases and clinical considerations". Semin Speech Lang. 30 (3): 162–73. doi:10.1055/s-0029-1225953. PMC 2805066. PMID 19711234. External links

Communication Disorders
Aphasia - National Institute on Deafness and Other Communication Disorders (NIDCD)
Dysgraphia - National Institute on Deafness and Other Communication Disorders Archived 2016-12-02 at the Wayback Machine
Voice and Speech Disorder Online Community (VoiceMatters.net)
List of communication disorder related links
Child Language Disorders
Tavaborole has an elimination half-life of 28.5 hours, a maximum concentration of 5.17 ng/mL after two weeks of daily use, and takes 8 days to reach the maximum concentration. Society and culture
Economics
Tavaborole began phase III clinical trials in December 2010 and was approved by the US FDA in July 2014.Originally developed by Anacor, it is now marketed in the United States by Novartis subsidiary Sandoz. Anacor was paid US$65 million and also entered into a profit sharing scheme for future sales. A 10 mL bottle of a 5% solution of tavaborole will cost the patient without insurance about $1,356. See also
Crisaborole – a structurally related topical medication used for the treatment of mild-to-moderate atopic dermatitis (eczema)

References
External links
"Tavaborole". Drug Information Portal. U.S. National Library of Medicine.